Lumida
/PROK
⌘K
ProKidney Corp

ProKidney Corp

PROK
$1.62USD+0.62%+0.01 today

MARKET CAP

489.3M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$2
$4

AI Summary

Stalk
StalkMedium

PROK remains in a high-confidence Stage 2 advancing phase with strong momentum signals from the recent breakout and structural repair. However, price is currently extended above the 9/21/50 EMAs with RSI and Options Score into overbought territory, increasing the risk of a near-term pullback. The medium-term bias stays bullish based on rising EMAs, volume expansion on advances, and multiple mean-reversion and continuation patterns. Execution is best deferred—await a pullback into the rising 9/21 EMA cluster and the prior breakout area around the former resistance zone for confirmation before initiating exposure.

  • Analysts’ $10 target implies >500% upside from $1.61
  • Q1 2026 narrow EPS beat validates rilparencel’s efficacy momentum
  • Clinical stage with no approved therapies limits revenue prospects
Full analysis →
Insider Trades8 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 8, 2025SellPROKDarin J. WeberChief Regulatory Officer103,480$3.02$489.3M-60.00%+5.88%$312.5K-100.00%10b5-1Stalk
Sep 19, 2024SellPROKDarin J. WeberChief Regulatory Officer16,412$2.50$489.3M-60.00%+5.88%$41.0K-13.69%10b5-1Stalk
Jul 26, 2024SellPROKDarin J. WeberChief Regulatory Officer826$2.50$489.3M-60.00%+5.88%$2.1K-0.68%10b5-1Stalk
Jun 18, 2024SellPROKDarin J. WeberChief Regulatory Officer17,238$2.82$489.3M-60.00%+5.88%$48.6K-12.50%10b5-1Stalk
May 20, 2024SellPROKDarin J. WeberChief Regulatory Officer17,238$4.08$489.3M-60.00%+5.88%$70.4K-11.11%10b5-1Stalk
Apr 18, 2024SellPROKDarin J. WeberSVP of Regulatory Development17,238$2.51$489.3M-60.00%+5.88%$43.3K-5.01%Stalk
Apr 16, 2024SellPROKDarin J. WeberSVP of Regulatory Development17,238$2.50$489.3M-60.00%+5.88%$43.1K-9.09%Stalk
Apr 1, 2024SellPROKDarin J. WeberSVP of Regulatory Development84,403$1.73$489.3M-60.00%+5.88%$146.0K-15.41%Stalk